111 related articles for article (PubMed ID: 10780265)
1. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Gaedigk A; Bertino JS
Pharmacogenetics; 1999 Aug; 9(4):453-62. PubMed ID: 10780265
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Rocci ML; Kulawy RW; Beck DJ; Bertino JS
Clin Pharmacol Ther; 1998 Sep; 64(3):257-68. PubMed ID: 9757149
[TBL] [Abstract][Full Text] [Related]
3. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity.
Ducharme J; Abdullah S; Wainer IW
J Chromatogr B Biomed Appl; 1996 Mar; 678(1):113-28. PubMed ID: 8861661
[TBL] [Abstract][Full Text] [Related]
4. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
[TBL] [Abstract][Full Text] [Related]
5. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
[TBL] [Abstract][Full Text] [Related]
6. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
7. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.
Kashuba AD; Bertino JS; Rocci ML; Kulawy RW; Beck DJ; Nafziger AN
Clin Pharmacol Ther; 1998 Sep; 64(3):269-77. PubMed ID: 9757150
[TBL] [Abstract][Full Text] [Related]
8. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.
Min DI; Ku YM; Vichiendilokkul A; Fleckenstein LL
Pharmacotherapy; 1999 Jun; 19(6):753-9. PubMed ID: 10391422
[TBL] [Abstract][Full Text] [Related]
9. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
10. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
11. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein.
Di Marco MP; Edwards DJ; Wainer IW; Ducharme MP
Life Sci; 2002 Jul; 71(10):1149-60. PubMed ID: 12095536
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of dextromethorphan N-demethylation activity as a biomarker for cytochrome P450 3A activity in man.
Kawashima Y; Hagiwara M; Inoue Y; Someya T
Pharmacol Toxicol; 2002 Feb; 90(2):82-8. PubMed ID: 12071430
[TBL] [Abstract][Full Text] [Related]
14. Single-point plasma or urine dextromethorphan method for determining CYP3A activity.
Kuo BP; Hu OY; Hsiong CH; Pao LH; Chen TS; Hung CF
Biopharm Drug Dispos; 2003 Dec; 24(9):367-73. PubMed ID: 14689465
[TBL] [Abstract][Full Text] [Related]
15. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes.
Kerry NL; Somogyi AA; Mikus G; Bochner F
Biochem Pharmacol; 1993 Feb; 45(4):833-9. PubMed ID: 8452558
[TBL] [Abstract][Full Text] [Related]
16. Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects.
Chládek J; Zimová G; Martínková J; Tůma I
Fundam Clin Pharmacol; 1999; 13(4):508-15. PubMed ID: 10456294
[TBL] [Abstract][Full Text] [Related]
17. A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition.
Vengurlekar SS; Heitkamp J; McCush F; Velagaleti PR; Brisson JH; Bramer SL
J Pharm Biomed Anal; 2002 Aug; 30(1):113-24. PubMed ID: 12151071
[TBL] [Abstract][Full Text] [Related]
18. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
19. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Shirey CS; Gotschall R; Gaedigk A; Bertino JS
Pharmacogenetics; 1998 Oct; 8(5):403-10. PubMed ID: 9825832
[TBL] [Abstract][Full Text] [Related]
20. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
Tracy TS; Venkataramanan R; Glover DD; Caritis SN;
Am J Obstet Gynecol; 2005 Feb; 192(2):633-9. PubMed ID: 15696014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
